ストックスクリーナーアプリを入手
30.56
8.61%
2.41
アフターアワーズ：
30.42
-0.14
-0.46%
前日終値:
$28.15
開ける：
$29.5
24時間の取引高:
42.78M
Relative Volume:
1.14
時価総額：
$6.97B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
58.53
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+6.09%
1か月 パフォーマンス:
+43.28%
6か月 パフォーマンス:
-37.32%
1年 パフォーマンス:
+8.65%
1日の値動き範囲:
$28.90
$31.33
1週間の範囲:
$27.03
$31.86
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
30.56 | 6.42B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.63 | 52.60B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.83 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.58 | 42.40B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 36.34B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
567.16 | 25.11B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot - TechStock²
HIMS Stock Rises as Options Activity Surges - GuruFocus
HIMS Stock Rises as J.P. Morgan Initiates Coverage with Overweig - GuruFocus
HIMS Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
How Expanding GLP‑1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story - Yahoo Finance
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims - Yahoo Finance
Hims rises as J.P. Morgan starts at Overweight (HIMS:NYSE) - Seeking Alpha
Hims & Hers (HIMS) Bets Big on Branded GLP-1s — J.P. Morgan Likes What It Sees - CoinCentral
HIMS Maintains Rating by B of A Securities -- Price Target Raised to $32 - GuruFocus
Hims & Hers Health (NYSE:HIMS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path - Stocktwits
JPMorgan initiates Hims & Hers stock at Overweight on GLP-1 outlook - Investing.com India
Dan Kenger Hims & Hers The Orange Pill Bottle Is Out And A Whole New Kind Of Healthcare Brand Is In - BuzzFeed
HIMS plunges 51.2% in 6 months: Should you still hold the stock or sell? - MSN
HIMS stock pares losses after-hours: Citi flags 'big caveat' in Amazon's GLP-1 push that limits risk to Hims model - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Hims & Hers Health - The National Law Review
Hims & Hers Health (HIMS) soars 11.1%: Is further upside left in the stock? - MSN
Hims stock falls as GLP-1 shift raises questions on strategy - TradingView
Hims Stock Falls on Pivot From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing. - Barron's
Hims stock price reacts strongly to crucial FDA review - thestreet.com
Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership - GuruFocus
Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch - Benzinga
Hims & Hers Health (NYSE:HIMS) Shares Gap UpWhat's Next? - MarketBeat
Hims & Hers (HIMS) Stock Surges 7% on Eli Lilly Weight Loss Drug Partnership Expansion - Blockonomi
Hims & Hers (HIMS) Stock Jumps 7% After Expanding Eli Lilly GLP-1 Deal - CoinCentral
AI for investors - MLQ.ai
+1.37% for Hims & Hers Health stock as Novo Nordisk Wegovy collaboration adds branded therapies - Traders Union
BofA raises Hims and Hers stock price target on Lilly partnership - Investing.com Canada
LLY Sees Surge as Hims & Hers Expands Prescription Capabilities - GuruFocus
Hims & Hers jumps 7% after expanding partnership with Eli Lilly - Yahoo Finance
Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days - Stocktwits
Hims & Hers Health Legal Chief Sells Shares Worth Over $280000 - Koran Manado
Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com Canada
Full Range of FDA-Approved GLP-1s Available on Hims & Hers - Hims & Hers Newsroom
Hims & Hers builds scalable data-driven personalized care platform - MSN
Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in? - TipRanks
HIMS Stock Slides Premarket: Rival Telehealth Firm Ro Launches Aggressive Price Cuts In GLP-1 Subscription Fight - Stocktwits
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock - Investing.com Canada
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock - Investing.com
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock By Investing.com - Investing.com Canada
Hims & Hers (HIMS) legal chief sells 9,463 shares in planned trade - Stock Titan
Hims & Hers (NYSE: HIMS) CFO option exercises and pre-planned share sale - Stock Titan
HIMS Expands Offerings for Menopause with Estrogen Patches - GuruFocus
Hims & Hers offers estrogen patches as US demand surges - USA Today
Hims & Hers says it has steady estrogen patch supply amid US shortages - Reuters
Hims & Hers doubles down on estrogen patches as demand surges - Seeking Alpha
HIMS Expands Into Menopause Care But Amazon’s GLP-1 Program Weighs On Stock - Stocktwits
Hims & Hers Health stock price forecast: $25.24 support in focus as HIMS slips 3.83% - Traders Union
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
Hims Hers Health Inc (HIMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Option Exercise |
8.65 |
12,553 |
108,531 |
282,599 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Sale |
29.96 |
19,645 |
588,615 |
262,954 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Option Exercise |
5.01 |
6,184 |
30,982 |
288,051 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 16 '26 |
Sale |
25.90 |
36,922 |
956,147 |
281,867 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Sale |
27.83 |
18,005 |
501,158 |
270,046 |
1.52%
1.90%
大文字化:
|
ボリューム (24 時間):